1. Introduction
===============

Cystic fibrosis (CF) results from mutation of the cystic fibrosis transmembrane regulator (CFTR) and leads to widespread organ-damaging fibrosis [@bib1] in pancreas, lung and liver [@bib2]. This suggests that there may be a profibrotic factor endogenous to CF-affected tissues. Tissue transglutaminase (tgase2) is one candidate, that catalyses the formation of ε-γ-glutamyl-lysine crosslinks between glutamine (Q) and lysine (K) residues on proteins in a Ca^2+^-dependent manner [@bib3]. Normally, this activity is silent inside cells, due to high GTP levels, but crosslinking has nevertheless been implicated in the regulation of tgase2 unrelated enzymatic activity [@bib4] and in the regulation of a protein kinase by oligomerisation [@bib5]. Here, we expand the theme linking tgase2 to kinase function in a disease context.

The regulation of tgase2 activity is not fully understood and a recent paper described disturbed tgase2 in CF [@bib6], finding that tgase2 is both over-expressed and over-active in CF cells. Our laboratory has been investigating the membrane-localised activity of nucleoside diphosphate kinase (nm23, NDPK-H1/H2 isoforms; ∼17 kDa) [@bib7; @bib8; @bib9; @bib10; @bib11; @bib12], a multifunctional, hexameric enzyme that not only regulates the balance of cellular nucleotides such as ATP/ADP and GTP/GDP but also controls multiple cellular processes [@bib13]. Unexpectedly, during the course of related studies using epithelial membranes derived from sheep tracheal epithelium, we repeatedly observed SDS- and mercaptoethanol-resistant, high molecular weight, NDPK-positive (HMW; ∼51 kDa) bands in membrane samples. These were not always present, suggestive of regulation and given that others had also reported unexpected ladders of high molecular weight NDPK species [@bib14], we speculated that these HMW, SDS-resistant bands could be cross-linked monomers that would otherwise have dissociated under reducing conditions in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Our results suggest that tgase2 can regulate NDPK activity.

2. Materials and methods
========================

SDS-PAGE, immunoblotting, immunoprecipitations and NDPK phosphorylation assays were carried out as previously described [@bib8; @bib12; @bib13]. Tgase2 was purchased from Calbiochem. All other reagents were from Sigma, except for radionuclides, obtained from NEN. Quantification of radioactivity was carried out by electronic autoradiography using an InstantImager (Packard). The anti-NDPK antibody used in this work (Santa Cruz) was raised against nm23-H1, but cross-reacts with nm23-H2; we do not distinguish between these two isoforms. Ovine tracheal samples were prepared as previously described [@bib15].

3. Results
==========

3.1. NDPK forms HMW species in ovine epithelial membranes
---------------------------------------------------------

Immunoblots of cytosolic and membrane protein from ovine airway epithelium probed for NDPK show that there is a HMW form ([Fig. 1](#fig1){ref-type="fig"}, lanes 1−3) that is only detected in the membrane compartment ([Fig. 1](#fig1){ref-type="fig"}, lanes 4+5: equal protein loading from cytosol and membrane, respectively). These unexpected bands corresponded to trimers of the 17 kDa NDPK monomer ([Fig. 1](#fig1){ref-type="fig"}, lanes 1--3). HMW bands were sometimes also observed in membranes from human epithelial cell lines (data not shown) and this led us to investigate the relationship between tgase2 and NDPK in human airway cells.

3.2. Tgase2 is elevated in a human CF cell model
------------------------------------------------

If tgase2 dysfunction is associated with the pathophysiology of CF [@bib6], tgase2 should be present in the affected tissues. Immunoblots show that tgase2 is present but there is nearly twice the level in cell membranes derived from CFBE cells, a human bronchial CF cell line expressing the ΔF508-CFTR when compared to the wild-type (WT) equivalent (HBE) ([Fig. 2](#fig2){ref-type="fig"}, lanes 1+2). Tgase2 activity can be inhibited by monodansylcadaverine (MDC) and cellular levels of tgase2 are strongly induced by retinoic acid (RA); these reagents are commonly used to manipulate tgase2 activity. Surprisingly RA treatment (5 μM, 5 days) reduced tgase2 in CFBE membranes three-fold to below that found in untreated WT HBE membranes ([Fig. 2](#fig2){ref-type="fig"}, compare lanes 4 and 1). The inhibitory effect of RA on HBE cell membrane tgase2 levels was more modest (lanes 3 and 1). By contrast, MDC treatment (50 μM, 5 days) of the cells dramatically reduced membrane-bound tgase2, but maintained the differential between WT and CF such that some residual tgase2 was detectable in CF but not wild-type cell membranes ([Fig. 2](#fig2){ref-type="fig"}, lanes 5+6).

3.3. NDPK co-immunoprecipitates with tgase2
-------------------------------------------

Anti-tgase2 immunoprecipitates from HBE and CFBE membranes were probed for associated NDPK. [Fig. 3](#fig3){ref-type="fig"} demonstrates that NDPK precipitates with tgase2 in both cell types and that the interaction is only abolished by an additional wash in 2 M NaCl suggesting tight association. Control precipitates with no antibody or irrelevant IgG were negative for NDPK.

3.4. NDPK activity can be altered by exogenous tgase2, but only if it originates from cytosol
---------------------------------------------------------------------------------------------

We incubated membrane and cytosolic fractions from HBE cells with exogenous tgase2, and then tested for NDPK activity. Membrane extracts were unaffected by tgase2, but cytosolic NDPK activity was reduced ([Fig. 4](#fig4){ref-type="fig"}). This is consistent with the idea that membrane-associated NDPK is already cross-linked or in some way resistant to the actions of transglutaminase for example by lying within a multiprotein complex involving the CFTR ion channel and AMP-activated protein kinase [@bib16; @bib17], so no change is observed.

3.5. NDPK activity is affected by tgase2 modulation
---------------------------------------------------

For unknown reasons, NDPK is dysfunctional in CF epithelium [@bib18]. We investigated whether the RA 'normalisation' of tgase2 levels would result in restoration of NDPK function in CF cells. We found that both the histidine autophosphorylation [@bib10] and the transferase activity of NDPK measured as GTP production [@bib7; @bib8] were restored to WT levels after a five-day treatment of CFBE cells with 5 μM RA ([Fig. 5](#fig5){ref-type="fig"}, bottom panels). MDC treatment also inhibited WT NDPK activity to similar levels to those found in CF ([Fig. 5](#fig5){ref-type="fig"}, top panels).

4. Discussion
=============

Thus, we have shown that NDPK can exist as a multimeric, SDS-resistant complex and that manipulation of tgase2 alters NDPK function. The difference in NDPK activity between CF membranes and wild-type membranes can be normalised. Our data also demonstrate that a fraction of cellular tgase2 co-immunoprecipitates with NDPK, suggesting that they are associated proteins.

Tgase2 is identical to the G-protein Gα~h~ [@bib19], implicating \[GTP\] in its regulation. One of the key roles of NDPK is maintenance of GTP levels local to G-proteins at the membrane [@bib20]. Ca^2+^ and GTP are antagonistic in their regulation of tgase2 activity; Ca^2+^ is stimulatory, GTP inhibitory. Its transglutaminase or GTPase activities are reported to predominate, depending on its subcellular localisation to cytosol or membrane, respectively [@bib21]. A disturbed tgase2-NDPK axis could have major implications, e.g. in the regulatory connection between tgase2 and the ras oncogene [@bib22], which affects NDPK activity [@bib23]. CFTR itself is regulated by unidentified G-proteins [@bib24; @bib25] and is also reported to be regulated by calcium *via* unknown pathways [@bib26]. Tgase2 has been reported to directly regulate adenylyl cyclase and, therefore, [@bib27; @bib28] is known to be both activated and induced by cyclic adenosine monophosphate (cAMP) [@bib29], the major activator of CFTR. We note that NDPK is also regulated by cAMP [@bib30].

The data in [Fig. 4](#fig4){ref-type="fig"} suggest that the activity of NDPK is specifically held in check in the membrane by drugs known to regulate tgase2. Interestingly, suitable Q/K residues for cross-linking exist in close proximity at interfaces between NDPK monomers [@bib31] and K31 and Q111 are conserved in the ubiquitous NDPK-H1 and H2 isoforms. There is only one report linking tgase2 activity with CF. Maiuri et al*.* [@bib6] showed recently that tgase2 activity is elevated in CF tissues and that PPARγ is a substrate for this activity. Here we suggest that NDPK is a further probable substrate for this excess cross-linking activity, which might explain our earlier observation of NDPK dysfunction in CF membranes [@bib18].

We have recently reported a complex relationship between membrane-local NDPK, its co-precipitating partner AMP-activated kinase, GTP and the differential phosphorylation of NDPK itself on histidine and serine residues. The latter was promoted by the presence of GTP [@bib13]. Since the GTP produced by NDPK could also regulate tgase2 activity, this relationship could form a tight feedback loop that could control the membrane-localised metabolic environment. In this context, it may be pertinent that membrane-bound, epithelial NDPK can interact with the metabolic sensor AMP-activated protein kinase (AMPK) [@bib13], which in turn is known to bind CFTR. Our observations on RA are unexpected in that they normalise NDPK function in CF whilst reducing tgase2 in the membrane. Others, whilst looking for ubiquitinated NDPK, observed curious ladders of NDPK high molecular weight species when they were expecting the usual smear of NDPK suggestive of poly-ubiquitination [@bib14]. Whatever the mechanism, our observed normalisation of tgase2 levels with RA treatment, coupled with the elevation of NDPK activity, indicates that RA (or tgase2 inhibitors) could be promising therapies for CF. Inhalation of aerosolised RA has already been tested as a therapy for lung cancer [@bib32] and as an alternative means of administering supplemental vitamin A [@bib33] making this route a viable approach to treat the CF lung. Thus two independent studies concur that tgase2 is overexpressed and is likely to be over-active in CF cells. Further investigation of tgase2 regulation is warranted in CF because fibrotic lung destruction is a major cause of CF morbidity.
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![NDPK immunoblots of ovine airway epithelial membrane protein separated on SDS-PAGE, showing consistent appearance of 51 kDa HMW bands in three independent preparations (lanes 1--3). Equivalent loadings of cytosolic (lane 4) and membrane (lane 5) protein showed that the HMW species is absent from the cytosolic fraction. The antibody used and the membrane preparation protocol are described in the methods for this and subsequent figures.](gr1){#fig1}

![Immunoblot and densitometric quantification of tgase2 (mouse monoclonal antibody cocktail, Neomarkers MS-300-p, 1:1000) in HBE and CFBE membranes isolated from cells pretreated with retinoic acid (RA, 5 μM, 5 days) and monodansylcadaverine (MDC, 50 μM, 5 days). Identical membrane protein loading (20 μg) was present in each lane.](gr2){#fig2}

![Immunoprecipitation from HBE and CFBE membranes using a specific anti-tgase2 antibody followed by immunoblotting for NDPK. The 'IP' sample in each case has been washed several times and represents NDPK bound to tgase. Control lanes show no antibody and irrelevant IgG samples. See Refs. [@bib7; @bib8; @bib9; @bib10; @bib11; @bib12] for methods.](gr3){#fig3}

![16HBE14o cytosolic or membrane extracts were incubated with exogenous tgase2 (1 μg, 4 h) and NDPK activity measured by its phosphorylation (for methods, see Ref. [@bib13]). Filled columns show data from samples without tgase2, white columns with tgase2. *n* = 3 ± S.E.M.](gr4){#fig4}

![Data showing NDPK phosphorylation (left) and phosphotransferase activity (right) in HBE and CFBE cell lines and the effect of treatment with RA (bottom) and MDC (top). For methods, see Ref. [@bib13]. *n* = 3 ± S.E.M.](gr5){#fig5}
